Combining blockers of the renin-angiotensin system or increasing the dose of an angiotensin II receptor antagonist in proteinuric patients: A randomized triple-crossover study

Journal of Hypertension

Volumn 29, Issue 6, 2011, Pages 1228-1235

  Meier, Pascal ^a,b   Maillard, Marc P ^a   Meier, Jacqueline R ^b   Tremblay, Sylvie ^a   Gauthier, Thierry ^c   Burnier, Michel ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Service of Nephrology and Hypertension   (Switzerland)

^c Hopital Riviera   (Switzerland)

Author keywords

albuminuria; angiotensin converting enzyme inhibitor; angiotensin receptor blocker; diabetes; hypertension; nephropathy

Indexed keywords

ALBUMIN; LISINOPRIL; LOSARTAN;

ADULT; AGED; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; URINARY ALBUMIN EXCRETION; URINARY EXCRETION;

EID: 85027932825     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328346d5dc     Document Type: Article

References (31)

1. Bakris GL. Microalbuminuria: prognostic implications. Curr Opin Nephrol Hypertens 1996; 5:219-223. (Pubitemid 26194553)
2. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, et al., AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139:244-252.
3. Hebert LA, Wilmer WA, Falkenhain ME, Ladson-Wofford SE, Nahman NS Jr, Rovin BH. Renoprotection: one or many therapies? Kidney Int 2001; 59:1211-1226. (Pubitemid 32281208)
4. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
5. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P, Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878.
6. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al., RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
7. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 1997; 349:1857-1863.
8. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensinconverting- enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456-1462. (Pubitemid 23335891)
9. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118:577-581. (Pubitemid 23102690)
10. Maschio G, Alberti D, Janin G, Locatelli F, Mann J, Motolese M, et al. for The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334:939-945.
11. Azizi M, Wuerzner G. Rationale for combining blockers of the reninangiotensin system. Semin Nephrol 2007; 27:544-554. (Pubitemid 47381469)
12. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME. Randomised controlled trial of dual blockade of reninangiotensin system in patients with hypertension, microalbuminuria, and noninsulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321:1440-1444.
13. Bakris GL, Weir MR. Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression. Postgrad Med 2008; 120:33-42.
14. MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis 2006; 48:8-20.
15. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK, AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358:2433-2446. (Pubitemid 351793017)
16. Forclaz A, Maillard M, Nussberger J, Brunner HR, Burnier M. Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor? Hypertension 2003; 41:31-36. (Pubitemid 36056788)
17. Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type .2. diabetes and microalbuminuria. Kidney Int 2005; 68:1190-1198. (Pubitemid 43246436)
18. Schmieder RE, Klingbeil AU, Fleischmann EH, Veelken R, Delles C. Additional antiproteinuric effect of ultrahigh dose candesartan: a doubleblind, randomized, prospective study. J Am Soc Nephrol 2005; 16:3038-3045. (Pubitemid 44743501)
19. Hollenberg NK, Parving H-H, Viberti G, Remuzzi G, Ritter S, Zelenkofske S, et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007; 25:1921-1926. (Pubitemid 47356634)
20. Ohishi M, Takagi T, Ito N, Tatara Y, Hayashi N, Shiota A, et al. Renal protective effect in hypertensive patients: the high doses of angiotensin II receptor blocker (HARB) study. Hypertens Res 2007; 30:1187-1192. (Pubitemid 351176416)
21. Burgess E, Muirhead N, de Cotret PR, Chiu A, Pichette V, Tobe S, and the SMART Investigators. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol 2009; 20:893-900.
22. Weinberg AJ, Zappe DH, Ramadugu R, Weinberg MS. Long-term safety of high-dose angiotensin receptor blocker therapy in hypertensive patients with chronic kidney disease. J Hypertens Suppl 2006; 24:S95-S99. (Pubitemid 44336830)
23. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al.,ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372:547-553.
24. Eknoyan G. Meeting the challenges of the new K/DOQI guidelines. Am J Kidney Dis 2003; 41:5 Suppl:S3-S10. (Pubitemid 36637963)
25. Gansevoort R, De Zeeuw D, De Jong P. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994; 45:861-867. (Pubitemid 24094500)
26. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, et al., African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285:2719-2728. (Pubitemid 32525368)
27. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. Ann Intern Med 2001; 135:73-87. (Pubitemid 32661190)
28. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148:30-48. (Pubitemid 351688350)
29. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, et al., for the HEAAL Investigators. Effects of high dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009; 374:1840-1848.
30. Viberti G, Wheeldon NM; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106:672-678. (Pubitemid 34851925)
31. Würzner G, Gerster JC, Chiolero A, Maillard M, Fallab-Stubi CL, Brunner HR, Burnier M. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout. J Hypertens 2001; 19:1855-1860. (Pubitemid 32924953)